PUBLISHER: DelveInsight | PRODUCT CODE: 1246751
PUBLISHER: DelveInsight | PRODUCT CODE: 1246751
"ENSPRYNG Emerging Drug Insight and Market Forecast - 2032" report provides comprehensive insights about ENSPRYNG for Generalized Myasthenia Gravis (gMG) in the seven major markets. A detailed picture of the ENSPRYNG for generalized myasthenia gravis in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the ENSPRYNG for generalized myasthenia gravis. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the ENSPRYNG market forecast analysis for generalized myasthenia gravis in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in generalized myasthenia gravis.
ENSPRYNG (satralizumab) is a humanized monoclonal antibody that targets the interleukin-6 (IL-6) receptor; gMG, a neuromuscular junction disorder, is caused by pathogenic autoantibodies. IL-6 plays important roles in T helper 17 (Th17), T follicular helper (Tfh), B-cell activation, and antibody production. Research shows that serum IL-6 levels were significantly increased and correlated with MG activity, which indicated the involvement of IL-6 in the pathogenesis of gMG through Th17, Tfh, and/or B-cells. Satralizumab is a selective IL-6R inhibitor and is administered subcutaneously.
ENSPRYNG was designed by Chugai Pharmaceutical, a subsidiary of Roche, using novel antibody recycling technology, which allows for a longer duration of antibody circulation and maximum inhibition of IL-6 signaling, while minimizing safety risks in a chronic disease setting. It is currently being studied in Phase III clinical trial as a monotherapy for the treatment of gMG in children and adults (patients aged 12 years or older).
The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
This report provides a detailed market assessment of ENSPRYNG for generalized myasthenia gravis in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2024 to 2032.
The report provides the clinical trials information of ENSPRYNG for generalized myasthenia gravis covering trial interventions, trial conditions, trial status, start and completion dates.